All In Biotech

Drug Trial Radar · NCT06358573

Intratumoral INT230-6 Followed by Neoadjuvant Immuno-chemotherapy in Patients With Early TNBC. INVINCIBLE-4-SAKK

Intratumoral INT230-6 Followed by Neoadjuvant Immuno-chemotherapy in Patients With Early Triple-negative Breast Cancer (TNBC). An Open-label Randomized Two-cohort Phase 2 Clinical Trial. INVINCIBLE-4-SAKK

Last checked: Nov 19, 2026Latest source record: Oct 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

61

Planned (sponsor's estimate)

Start

Oct 24, 2024

Primary completion

Oct 2028

Study completion Dec 2031

Sponsor

Lead sponsor
Swiss Cancer InstituteAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Apr 10, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

About 10-20% of all individuals with breast cancer have a so-called triple-negative tumor (TNBC). This type of breast cancer has a particularly unfavorable course and a higher mortality rate compared to other forms of breast cancer. Research studies show that it is important for individuals with TNBC to achieve a so-called pathologic complete response (pCR) to treatment. In the phase II study SAKK 66/22, it is being investigated whether the administration of the drug INT230-6 before surgery for breast cancer can increase the rate of pCR in the tumor and affected lymph nodes. The tolerability of INT230-6 as well as other factors such as response to treatment and the possibility of breast-conserving surgery are also being examined.

Conditions

  • Triple-negative Breast Cancer
  • TNBC - Triple-Negative Breast Cancer

Interventions

  • INT230-6Drug

    INT230-6 is a formulation consisting of an proprietary amphiphilic cell penetration enhancer molecule, 8-((2-hydroxybenzoyl)amino)octanoate, also referred to as SHAO, combined with cisplatin and vinblastine sulfate. The IMP is without marketing authorization in Switzerland and anywhere in the world.

  • neoadjuvant immuno-chemotherapyOther

    Standard of care

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Pathological complete response (pCR) in the primary tumor (ypT0/Tis) and affected lymph nodes (ypN0).Time frame: At the date of tumor assessment after surgery, estimated at 29 to 32 weeks after treatment start for cohort A and at 27 to 30 weeks after treatment start for cohort B.

Locations

10 sites in 2 countries. Site status is shown where the registry gives one.

  • Centre de lutte contre le cancer Léon Bérard

    Lyon, France · Recruiting

  • Tumor Zentrum Aarau

    Aarau, Switzerland · Terminated

  • St. Claraspital

    Basel, Switzerland · Recruiting

  • EOC - IOSI Ospedale regionale Bellinzona e valli - San Giovanni

    Bellinzona, Switzerland · Recruiting

  • Kantonsspital Graubünden

    Chur, Switzerland · Recruiting

  • Kantonsspital Baselland

    Liestal, Switzerland · Recruiting

  • HOCH Health Ostschweiz

    Sankt Gallen, Switzerland · Recruiting

  • TBZO - Tumor- & Brustzentrum Ostschweiz

    Sankt Gallen, Switzerland · Active not recruiting

  • Kantonsspital Winterthur

    Winterthur, Switzerland · Recruiting

  • Universitätsspital Zürich - Klinik für Gynäkologie

    Zurich, Switzerland · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.